Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arnab K Chatterjee

Showing results (81-90 of 102) with videos related to

Pageof 11
Sort By:
Antimicrobial Agents and Chemotherapy|December 25, 2013
KAI407, a potent non-8-aminoquinoline compound that kills Plasmodium cynomolgi early dormant liver stage parasites in vitroAnne-Marie Zeeman, Sandra M van Amsterdam, Case W McNamara, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of tetrahydropyrazolopyrimidine carboxamide derivatives as potent and orally active antitubercular agentsFumiaki Yokokawa, Gang Wang, Wai Ling Chan, et al.
Science (New York, N.Y.)|August 22, 2020
Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimeticEmily N Chin, Chenguang Yu, Vincent F Vartabedian, et al.
Biorxiv : the Preprint Server for Biology|June 5, 2026
Substrate and target selectivity of 4'-fluoroadenosine against viral and host polymerasesSimon M Walker, Arlo J Loutan, Egor P Tchesnokov, et al.
The Journal of Biological Chemistry|July 6, 2026
Substrate and target selectivity of 4'-fluoroadenosine against viral and host polymerasesSimon M Walker, Arlo J Loutan, Egor P Tchesnokov, et al.
Biorxiv : the Preprint Server for Biology|April 12, 2022
Targeted protein S-nitrosylation of ACE2 as potential treatment to prevent spread of SARS-CoV-2 infectionChang-Ki Oh, Tomohiro Nakamura, Nathan Beutler, et al.
Nature Chemical Biology|September 29, 2022
Targeted protein S-nitrosylation of ACE2 inhibits SARS-CoV-2 infectionChang-Ki Oh, Tomohiro Nakamura, Nathan Beutler, et al.
Nature Communications|February 8, 2024
Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitorSvenja M Sake, Xiaoyu Zhang, Manoj Kumar Rajak, et al.
ACS Medicinal Chemistry Letters|August 23, 2014
Lead optimization of imidazopyrazines: a new class of antimalarial with activity on Plasmodium liver stagesBin Zou, Advait Nagle, Arnab K Chatterjee, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2020
A Large-scale Drug Repositioning Survey for SARS-CoV-2 AntiviralsLaura Riva, Shuofeng Yuan, Xin Yin, et al.
Pageof 11

Showing results (81-90 of 102) with videos related to

Sort By:
Pageof 11
Antimicrobial Agents and Chemotherapy|December 25, 2013
KAI407, a potent non-8-aminoquinoline compound that kills Plasmodium cynomolgi early dormant liver stage parasites in vitroAnne-Marie Zeeman, Sandra M van Amsterdam, Case W McNamara, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of tetrahydropyrazolopyrimidine carboxamide derivatives as potent and orally active antitubercular agentsFumiaki Yokokawa, Gang Wang, Wai Ling Chan, et al.
Science (New York, N.Y.)|August 22, 2020
Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimeticEmily N Chin, Chenguang Yu, Vincent F Vartabedian, et al.
Biorxiv : the Preprint Server for Biology|June 5, 2026
Substrate and target selectivity of 4'-fluoroadenosine against viral and host polymerasesSimon M Walker, Arlo J Loutan, Egor P Tchesnokov, et al.
The Journal of Biological Chemistry|July 6, 2026
Substrate and target selectivity of 4'-fluoroadenosine against viral and host polymerasesSimon M Walker, Arlo J Loutan, Egor P Tchesnokov, et al.
Biorxiv : the Preprint Server for Biology|April 12, 2022
Targeted protein S-nitrosylation of ACE2 as potential treatment to prevent spread of SARS-CoV-2 infectionChang-Ki Oh, Tomohiro Nakamura, Nathan Beutler, et al.
Nature Chemical Biology|September 29, 2022
Targeted protein S-nitrosylation of ACE2 inhibits SARS-CoV-2 infectionChang-Ki Oh, Tomohiro Nakamura, Nathan Beutler, et al.
Nature Communications|February 8, 2024
Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitorSvenja M Sake, Xiaoyu Zhang, Manoj Kumar Rajak, et al.
ACS Medicinal Chemistry Letters|August 23, 2014
Lead optimization of imidazopyrazines: a new class of antimalarial with activity on Plasmodium liver stagesBin Zou, Advait Nagle, Arnab K Chatterjee, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2020
A Large-scale Drug Repositioning Survey for SARS-CoV-2 AntiviralsLaura Riva, Shuofeng Yuan, Xin Yin, et al.
Pageof 11